InfuSystem Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by InfuSystem Holdings, Inc. on May 20, 2020. The filing addresses Item 5.02 regarding the approval and grant of compensatory arrangements to the Company's named executive officers under the 2014 Equity Plan.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structure of equity compensation awards rather than reporting period financial results.
Material Changes and Compensation Details
On May 20, 2020, the Board of Directors approved a form of Performance Unit Award Agreement and granted the following 2020 long-term equity compensation to named executive officers:
- Rich DiIorio (President and CEO): 15,000 Performance Units and 25,000 stock options.
- Carrie Lachance (COO): 10,000 Performance Units and 20,000 stock options.
- Barry Steele (CFO): 7,500 Performance Units and 15,000 stock options.
- Thomas Ruiz (CCO): 10,000 Performance Units and 20,000 stock options.
- Jeannine Sheehan (CAO): 10,000 Performance Units and 20,000 stock options.
Performance Unit Terms:
- Performance Period: Calendar year ending December 31, 2021.
- Vesting Date: May 20, 2022.
- Metrics: 50% based on Net Revenue and 50% based on Adjusted EBITDA Margin (AEBITDA Margin).
- Payout Scale: Ranges from 0% (below threshold) to 200% (maximum ceiling) of the target award.
- Forfeiture: Unvested units are forfeited upon termination of employment.
- Change of Control: All outstanding units vest as if the "target" performance goal was achieved.
Stock Option Terms:
- Exercise Price: $11.07 per share (fair value on grant date).
- Vesting Schedule: Three equal annual installments beginning May 20, 2021.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard forfeiture provisions tied to employment termination. The awards are contingent on future performance metrics (Net Revenue and AEBITDA Margin) for the 2021 period.
Key Facts for Investor Verification
- Verify the specific "threshold," "target," and "maximum ceiling" performance goals for Net Revenue and AEBITDA Margin, as these determine the actual payout value (0% to 200%) and are not detailed in this summary.
- Confirm the total number of shares available under the 2014 Equity Plan to assess the dilution impact of these grants.
- Review the full text of Exhibit 10.1 (Form of Performance Unit Award Agreement) for detailed definitions of "AEBITDA Margin" and any potential adjustments.
- Monitor the Company's stock price relative to the $11.07 exercise price to evaluate the intrinsic value of the granted stock options.